JMP Securities Reiterates “Market Outperform” Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “market outperform” rating reiterated by equities research analysts at JMP Securities in a research report issued on Tuesday,Benzinga reports. They currently have a $21.00 target price on the biotechnology company’s stock. JMP Securities’ price target suggests a potential upside of 258.36% from the company’s previous close.

ENTA has been the subject of several other reports. Robert W. Baird reduced their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday. Two analysts have rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Stock Performance

ENTA opened at $5.86 on Tuesday. The firm has a market capitalization of $124.99 million, a PE ratio of -1.07 and a beta of 0.54. Enanta Pharmaceuticals has a 52-week low of $4.71 and a 52-week high of $17.80. The business’s 50-day simple moving average is $5.80 and its 200 day simple moving average is $9.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. On average, research analysts forecast that Enanta Pharmaceuticals will post -5.05 earnings per share for the current year.

Insider Activity

In related news, CEO Jay R. Luly acquired 45,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The shares were bought at an average cost of $5.69 per share, with a total value of $256,050.00. Following the completion of the purchase, the chief executive officer now directly owns 846,638 shares in the company, valued at $4,817,370.22. The trade was a 5.61 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 13.89% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. AlphaQuest LLC raised its position in shares of Enanta Pharmaceuticals by 16.4% in the 4th quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 3,137 shares in the last quarter. American Century Companies Inc. increased its holdings in Enanta Pharmaceuticals by 10.5% in the fourth quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 3,501 shares in the last quarter. US Bancorp DE increased its holdings in Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 4,243 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Enanta Pharmaceuticals in the fourth quarter valued at approximately $26,000. Finally, Quest Partners LLC boosted its holdings in shares of Enanta Pharmaceuticals by 65.0% during the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock worth $198,000 after buying an additional 7,535 shares in the last quarter. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.